Study of clinical experience with different approaches to controlled ovarian hyperstimulation: a focus on safety and efficacy

Objectives Current retrospective cohort study analyses clinical database records of 4792 assisted reproduction procedures to assess the significance of target effectiveness endpoints from a safety perspective. Methods Stimulation protocols with urinary, recombinant or combination of both types gonadotrophin preparations are compared according to the following primary endpoints: incidence of ovarian hyperstimulation syndrome (OHSS), cycle cancellation, follicle count, induced estradiol values, clinical pregnancy achieved and cycles reached embryo transfer/freezing. We have investigated the incidence of cases evaluated as 'risky for OHSS' by secondary efficacy endpoints (exogenous gonadotrophin exposure, luteinising hormone and progesterone values, oocyte yield, eggs with normal maturation). The following statistical methods were applied: descriptive statistics, Mann-Whitney U test, Kruskal-Wallis test, Pearson chi-square test, Fisher's exact test, binary logistic regression. Results Only 16 cases (0.42%) of moderate and delayed OHSS were established. Three hundred and seven (8.6%) stimulation cycles have been cancelled, principally among urinary protocols. Although the clinical pregnancy rate does not differ significantly in compared groups, punctured follicle count, oocyte yield and progesterone level were higher for recombinant preparations, followed by combined and urinary protocols. Follicle count, mean estradiol and luteinising hormone levels are within the 'safe window' for all investigated groups, associated with minimised risk of stimulation cancellation. The mean follicle-stimulating hormone (FSH) dose was highest in urinary protocols at the same duration of stimulation compared with recombinant products. The younger age, bigger follicle count, oocytes yield, mature oocytes count, percentage of fertilised oocytes, more embryos transferred and the later day of embryo transfer are critical for both assisted reproduction techniques (ART) success rate and the safety profile of sterility treatment. Conclusions Safety surveillance of ART exceeds the incidence of OHSS. Suboptimal effectiveness of stimulation protocols may also jeopardise the well-being of ART patients. Gonadotrophin exposure, induced values of sex hormones, and quantity and quality of extracted oocytes should be considered to minimise any unintended suffering of treated couples.

[1]  P. Humaidan,et al.  Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders , 2017, Human reproduction.

[2]  Y. L. Chen,et al.  [A randomized, single-blind, parallel-controlled and multicentre study: compare the efficacy and safety of domestic and imported human recombinant FSH in WHO group Ⅱ anovulatory infertility]. , 2016, Zhonghua fu chan ke za zhi.

[3]  Morton B. Brown,et al.  Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles. , 2015, Fertility and sterility.

[4]  P. Humaidan,et al.  Efficacy and Safety of Pergoveris in Assisted Reproductive Technology—ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment , 2015, BMJ Open.

[5]  P. Patrizio,et al.  Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. , 2015, Human reproduction update.

[6]  A. Obruca,et al.  A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF. , 2015, Reproductive biomedicine online.

[7]  Seth R. Flaxman,et al.  National, Regional, and Global Trends in Infertility Prevalence Since 1990: A Systematic Analysis of 277 Health Surveys , 2012, PLoS medicine.

[8]  J. M. Tenías,et al.  Pharmaceutical care for patients undergoing assisted reproduction techniques , 2012 .

[9]  D. Ezcurra,et al.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment , 2012, Reproductive Biology and Endocrinology.

[10]  M. Eijkemans,et al.  Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. , 2011, Human reproduction update.

[11]  N. Laufer,et al.  Ovarian Hyperstimulation Syndrome: Definition, Incidence, and Classification , 2010, Seminars in reproductive medicine.

[12]  C. Simón,et al.  Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. , 2010, Human reproduction.

[13]  E. Kolibianakis,et al.  Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. , 2008, Human reproduction.

[14]  G. Pennings,et al.  Coming soon to your clinic: patient-friendly ART. , 2007, Human reproduction.

[15]  S. Moon,et al.  Comparison of the efficacy and safety of a new recombinant human follicle‐stimulating hormone (DA‐3801) with follitropin‐α (Gonal‐F®) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology , 2007, The journal of obstetrics and gynaecology research.

[16]  P. Devroey,et al.  Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. , 2006, Human reproduction.

[17]  S. Moon,et al.  Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology. , 2007, The journal of obstetrics and gynaecology research.

[18]  M. Sedler,et al.  Management of ovarian hyperstimulation syndrome , 2006 .

[19]  L. Natarajan,et al.  The concerns during assisted reproductive technologies (CART) scale and pregnancy outcomes. , 2004, Fertility and sterility.